中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (7): 562-565.doi: 10.35541/cjd.20220077

• 论著 • 上一篇    下一篇

度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察

高子蕊    赵培    窦沅青    刘萍    张建中   

  1. 北京大学人民医院皮肤科，北京  100044
  • 收稿日期:2022-02-07 修回日期:2022-05-06 发布日期:2022-07-05
  • 通讯作者: 张建中 E-mail:rmzjz@126.com

Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis

Gao Zirui, Zhao Pei, Dou Yuanqing, Liu Ping, Zhang Jianzhong   

  1. Department of Dermatology, Peking University People′s Hospital, Beijing 100044, China
  • Received:2022-02-07 Revised:2022-05-06 Published:2022-07-05
  • Contact: Zhang Jianzhong E-mail:rmzjz@126.com

PDF

35

摘要： 【摘要】 目的 观察度普利尤单抗治疗结节性痒疹的疗效和安全性。方法 本研究为前瞻性研究。2021年1 - 10月在北京大学人民医院收集结节性痒疹患者，给予度普利尤单抗治疗。分别于第0、4、16周使用研究者整体评估（IGA）、数字评价量表（NRS）以及皮肤病生活质量指数（DLQI）评估疗效。用Wilcoxon符号秩检验和配对t检验对比分析治疗前后的评分变化。结果 共纳入17例患者，女12例，男5例，年龄（48.47 ± 16.26）岁。度普利尤单抗治疗16周时，NRS瘙痒评分由基线（8.00 ± 1.50）分降至（1.29 ± 0.85）分（t = 6.98，P＜0.001），NRS睡眠影响评分由（5.18 ± 2.98）分下降至（0.12 ± 0.49）分（t = 12.55，P＜0.001），DLQI指数由（13.29 ± 4.03）分降至（0.88 ± 0.70）分（t = 16.39，P＜0.001）；同时，所有患者由IGA 3 ~ 4级下降至IGA 0 ~ 2级，16例达到IGA 0 ~ 1级；12例达到IGA活动性0级。治疗过程中2例出现轻度结膜炎，1例出现局部注射反应，均在短暂对症处理后好转。结论 度普利尤单抗治疗成人结节性痒疹疗效显著且安全性良好。

关键词: 痒疹, 皮炎, 特应性, 生物制剂, 治疗结果, 药物毒性, 度普利尤单抗, 结节性痒疹

Abstract: 【Abstract】 Objective To evaluate the efficacy and safety of dupilumab in the treatment of adult prurigo nodularis. Methods A prospective study was conducted on patients with prurigo nodularis who received the treatment with dupilumab in Peking University People′s Hospital from January 2021 to November 2021. Efficacy was assessed using the Investigator′s Global Assessment （IGA）, Numerical Rating Scale （NRS） and Dermatology Life Quality Index （DLQI） at weeks 0, 4 and 16. Wilcoxon signed-rank test and paired t test were used to analyze changes in the above parameters before and after treatment. Results A total of 17 patients were enrolled in this study, including 12 females and 5 males, aged 48.47 ± 16.26 years. After 16-week treatment with dupilumab, the pruritus NRS score decreased from 8.00 ± 1.50 at baseline to 1.29 ± 0.85 （t = 6.98, P < 0.001）, the sleeplessness NRS score decreased from 5.18 ± 2.98 at baseline to 0.12 ± 0.49 （t = 12.55，P < 0.001）, and the DLQI score declined from 13.29 ± 4.03 at baseline to 0.88 ± 0.70 （t = 16.39，P < 0.001）; at week 16, the IGA grade of all the 17 patients decreased from 3 - 4 at baseline to 0 - 2, 16 achieved IGA grades 0 - 1, and 12 achieved IGA grade 0. During the treatment, mild conjunctivitis occurred in 2 cases, local injection reaction occurred in 1, and both conditions were improved after short-term symptomatic treatment. Conclusion Dupilumab is markedly effective and safe in the treatment of adult prurigo nodularis.

Key words: Prurigo, Dermatitis, atopic, Biological agents, Treatment outcome, Drug toxicity, Dupilumab, Prurigo nodularis